Iain is Head of Life Sciences at Cambridge Enterprise, responsible for a team that is working across the life sciences sector from human health therapeutics to agritech and research tools. Iain has a PhD in Organic Chemistry (Sydney) and MBA (Cambridge).
The team has spun-out companies including X01 Therapeutics, Apcintex (now a Centessa company), DIOSynVax, NoBACZ Healthcare, Predictimmune Limited, PhoreMost, Z-factor and Cambridge Epigenetix. Iain, with colleagues from partner universities founded Apollo Therapeutics, a £40 million fund in early stage drug development and launched the Ceres Agritech Knowledge Exchange Partnership. Iain also led discussions with GSK in respect of the University of Cambridge-GSK open innovation drug discovery initiative based at the Stevenage Bioscience Catalyst.
Iain joined Cambridge Enterprise in November 2003.